Podcast Episodes
Back to Search
Big Pharma bounces back in Q2
After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the se…
10 months, 2 weeks ago
The battle of the obesity drug heavyweights
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after quarte…
10 months, 3 weeks ago
Is Trump’s MFN pricing order more bark than bite?
Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored Nation drug pricing ref…
11 months ago
Rebuilding trust: compassionate communication and public health (Sponsored)
In the latest episode of Health Matters, vaccine expert Dr. Paul Offit joins host Wendy Lund to discuss the growing crisis of vaccine hesitancy and w…
11 months ago
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny …
11 months, 1 week ago
Making sense of China’s R&D ascent
With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised t…
11 months, 2 weeks ago
AI, mentorship and finding your voice in pharma marketing
In this episode of "The Top Line," Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, sits down with two longtime industry leaders…
11 months, 3 weeks ago
Biopharma layoffs aren't letting up
Layoffs in biopharma show no signs of slowing, with workforce reductions holding steady across the first two quarters of 2025.
In this week’s episode…
11 months, 4 weeks ago
Peter Pitts talks FDA direction, industry communication (Sponsored)
In the latest episode of the Health Matters podcast, Wendy Lund sits down with Peter Pitts, former FDA associate commissioner and current president o…
1 year ago
Teva’s CEO shares ‘Pivot to Growth’ progress
Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive…
1 year ago